Shanghai MicroPort EP MedTech's (SHA:688351) forecasts its attributable profit will rise 76% to 106% to between 30 million yuan and 35 million yuan in the first half from 17 million yuan in the prior-year period, according to a Wednesday filing with the Shanghai bourse.

Operating income at the medical device company is seen to grow 8.4% to 16% to between 215 million yuan and 230 million yuan during the half, from 198.4 million yuan in the year-ago period.

The upbeat forecast is attributable to steady growth in its overall sales volume following the launch of its TrueForce pressure monitoring radiofrequency ablation catheters, the filing said.